deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02865135

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients

Sponsor: Dana-Farber Cancer Institute

Conditions Cancer of Anus Cancer of Cervix Cancer of Head and Neck
Interventions Cyclophosphamide DPX-E7 vaccine
Updated 15 times since 2017 Last updated: Jan 10, 2024 Started: Mar 30, 2017 Primary completion: Oct 4, 2019 Completion: Feb 6, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Cancer of Anus and Cancer of Cervix and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Feb 2024 · 23 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Oct 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Nov 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Stand Up To Cancer
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations